13F Holdings
中文EN

GH Guardant Health, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1576280 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.0%
TTM net income YoY9.0%
TTM EPS YoY16.8%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—

Margins

Gross margin60.8%
Operating margin-60.0%
Net margin-59.0%
FCF margin-37.2%
EBITDA margin-54.4%

Returns

ROE-4,584.5%
ROA-26.7%
ROIC (approx.)—
Asset turnover0.45x

Leverage & solvency

Liabilities / assets109.4%
Debt / equity—
Current ratio4.68x
Interest coverage-171.87x

Cash quality & payout

Operating cash flow / net income0.55x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue4.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$982.02M$739.02M$563.95M$449.54M$373.65M
Cost of revenue$349.01M$289.80M$227.05M——
Gross profit$633.01M$449.22M$336.90M——
R&D expense$364.19M$347.75M$367.19M$373.81M$263.22M
SG&A expense$211.41M$180.12M$155.80M$163.96M$206.64M
Operating income-$437.25M-$443.59M-$564.73M-$544.38M-$411.00M
Interest expense$3.90M$2.58M$2.58M$2.58M$2.58M
Pretax income-$417.54M-$435.09M-$478.76M-$653.45M-$384.47M
Income tax-$1.26M$1.28M$685,000$1.14M$300,000
Net income-$416.28M-$436.37M-$479.45M-$654.59M-$384.77M
EBITDA-$397.51M-$401.21M-$521.84M-$508.42M-$388.73M
EPS (basic)-3.32-3.56-4.28-6.41-4.00
EPS (diluted)-3.32-3.56-4.28-6.41-4.00
Weighted avg. shares (diluted)125.37M122.75M111.99M102.18M101.31M
Balance sheet
Cash & equivalents$378.20M$629.75M$1.13B$141.95M$492.29M
Short-term investments$823.39M$314.44M$35.10M$869.58M$440.55M
Receivables$137.85M$110.25M$88.78M$97.26M$97.65M
Inventory$85.88M$71.08M$61.95M$51.60M$30.67M
Current assets$1.47B$1.06B$1.35B$1.19B$1.11B
PP&E, net$145.91M$136.81M$145.10M$167.92M$124.46M
Goodwill$77.26M$3.29M$3.29M$3.29M$3.29M
Intangibles$25.92M$6.76M$8.98M$11.73M$14.21M
Total assets$2.01B$1.49B$1.79B$1.61B$2.20B
Current liabilities$302.73M$225.58M$205.92M$193.22M$194.69M
Long-term debt$1.50B$1.14B———
Total debt$1.50B$1.14B———
Total liabilities$2.11B$1.63B$1.63B$1.55B$1.56B
Shareholders' equity-$99.31M-$139.65M$158.68M$60.18M$645.00M
Net debt$1.13B$512.79M———
Shares outstanding130.64M123.99M121.63M102.62M101.77M
Cash flow statement
Operating cash flow-$184.76M-$239.86M-$324.98M-$309.46M-$209.02M
Capital expenditure$48.31M$35.09M$20.49M$77.46M$75.03M
Free cash flow-$233.07M-$274.94M-$345.46M-$386.92M-$284.05M
Investing cash flow-$627.20M-$261.31M$840.25M$149.82M-$63.16M
Financing cash flow$671.13M-$996,000$477.38M-$189.09M-$66.82M
Depreciation & amortization$39.74M$42.39M$42.88M$35.96M$22.27M
Stock-based compensation$166.22M$140.41M$90.76M$94.69M$151.45M
Share buybacks$45.01M$0$0——

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.